PARP抑制剂在卵巢癌治疗中的耐药机制及克服耐药策略的研究进展

doi:10.3969/j.issn.2095-1264.2025.01.03

首页 > 过刊浏览>2025年第1期 >21-31. DOI:10.3969/j.issn.2095-1264.2025.01.03

PARP抑制剂在卵巢癌治疗中的耐药机制及克服耐药策略的研究进展
DOI:
                        10.3969/j.issn.2095-1264.2025.01.03
                    
作者:
                        
                        
                    
作者单位:华南恶性肿瘤防治全国重点实验室/广东省恶性肿瘤临床医学研究中心/中山大学肿瘤防治中心， 广东 广州，510060
作者简介:郝静，女，博士研究生，研究方向为生物与医药。
通讯作者:谭静，男，博士，教授，研究方向为表观遗传调控与肿瘤治疗抵抗。
中图分类号:R737.31
基金项目:

Research progress of drug resistance mechanism of PARP inhibitors in ovarian cancer treatment and strategies to overcome drug resistance

Author:

Affiliation:

State Key Laboratory of Oncology in South China / Guangdong Clinical Research Center for Cancer / Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

多腺苷二磷酸核糖聚合酶抑制剂（PARPi）是一种十分有效的卵巢癌靶向治疗手段。已有多种PARPi被批准用于卵巢癌一线治疗和复发后的维持治疗。尽管PARPi应用前景广阔，但耐药问题十分突出。近年来，PARPi的耐药机制及克服耐药的策略已成为国内外研究热点，本文综述了PARPi治疗卵巢癌的最新进展及其耐药机制，旨在为扩大PARPi的临床应用提供思路和参考。

Abstract:

The poly (ADP-ribose) polymerase inhibitors (PARPi) represent a highly effective targeted therapeutic approach for ovarian cancer. Various PARPi have been approved for the first-line treatment of ovarian cancer and maintenance therapy after recurrence. Despite their broad application prospects, the prominent issue of drug resistance remains a critical challenge. In recent years, studies related to the resistance mechanism of PARPi and strategies to overcome drug resistance have become a research focus both domestically and internationally. This article reviews the latest advancements in PARPi-based therapies for ovarian cancer and their resistance mechanism, aiming to provide insights and references for expanding the clinical application of PARPi.